{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 66,
  "pageCount": 415,
  "prevPage": 65,
  "nextPage": 67,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "This slide is part of a series of 'investigator' profiles used to build a case against a company's clinical trial results.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/66",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-66",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Expressed extreme concern about pulmonary edema and cardiac failure, based on extensive experience using diazoxide for hyperinsulinism",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-78b3f297af92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.85,
        "x": 0.07,
        "y": 0.73
      },
      "kind": "list",
      "text": "The investigator indicated that PWS patients are already at risk of elevated pulmonary pressures, thereby exacerbating the risk of cardiac events: “they’re likely to have problems with their left ventricular function...as a result of obesity and blood pressure...you don’t know it until you start a drug that increases pulmonary pressures...that is one thing I would worry about...that’s the side effect that worries me with this drug.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2423e66c-83ea-4981-a167-801b5d708599",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.85,
        "x": 0.07,
        "y": 0.57
      },
      "kind": "list",
      "text": "Expressed extreme concern about pulmonary edema and cardiac failure, based on extensive experience using diazoxide for hyperinsulinism – “in the other condition we use diazoxide for, pulmonary edema is a massive concern of ours...the main adverse event that I would be worried about with this drug and the potential for that...difficult to predict who will develop that...personally, I would always be ordering echos on any child before and during treatment.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29fa20ac-aa3e-46e6-ac10-52106913c11b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.17
      },
      "kind": "list",
      "text": "Harshly criticized the Soleno trials; implied that all or most patients discontinued Vykat and dropped out of the trial; indicated “massive concern” about cardiac risk and pulmonary edema; and stated that generic diazoxide liquid suspension is “always going to be better” anyway.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "823fa2b9-fea0-4024-8a9d-e172ee16f15d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.85,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "list",
      "text": "Indicated that the trial was functionally unblinded due to hair growth and edema, making it easy to deduce who was on drug; and because Vykat tablets smelled different than placebo, which families figured out: “the hair things is really difficult and same with the edema...you’ll never be able to blind that properly”; “the smell was mentioned by one of them...patients in our group are on social media and the family forums.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0100629-8b8b-4a09-a10c-95550432a124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.29
      },
      "kind": "list",
      "text": "Stated that the HQ-CT hyperphagia endpoint is unreliable and useless: “any kind of score like that...possible to manipulate it”; “skewed if they have overexaggerated” baselines scores; “I don’t think the HQ-CT score is very good”; “perception of hyperphagia is a tricky one to quantify.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6303e15-08cc-452c-814e-4acdfeadaffe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“any kind of score like that...possible to manipulate it”; “the hair things is really difficult and same with the edema...you’ll never be able to blind that properly”; “that is one thing I would worry about...that’s the side effect that worries me with this drug.” — Trial investigator #6",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-7d877e3abb95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61920888-eac0-4144-9e05-0926eb4fd0ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #6: Clinician and researcher with ~30-35 PWS patients and participated in the phase 3, open-label, and withdrawal studies.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "340c50b2-7f69-4577-959e-a19db1aeaf08",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Anadiplosis",
      "slug": "anadiplosis",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8429b073-d829-4991-a2d4-a0f91e4e3330",
      "evidence": "The investigator indicated that PWS patients are already at risk of elevated pulmonary pressures, thereby exacerbating the risk of cardiac events: “they’re likely to have problems with their left ventricular",
      "confidence": 0.7
    },
    {
      "name": "Call-and-Response",
      "slug": "call-and-response",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "1fe2dada-059f-4c70-af6b-ae92968b940e",
      "evidence": "Stated that the trial was functionally unblinded due to hair growth and edema, making it easy to deduce who was on drug; and because Vykat tablets smelled different than placebo, which families figured ou",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}